Renoprotective effects of dulaglutide in patients with T2DM and CKD

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Standard

Renoprotective effects of dulaglutide in patients with T2DM and CKD. / Sorensen, Charlotte M; Holst, Jens J.

I: Nature Reviews. Nephrology, Bind 14, Nr. 11, 2018, s. 659-660.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Harvard

Sorensen, CM & Holst, JJ 2018, 'Renoprotective effects of dulaglutide in patients with T2DM and CKD', Nature Reviews. Nephrology, bind 14, nr. 11, s. 659-660. https://doi.org/10.1038/s41581-018-0055-x

APA

Sorensen, C. M., & Holst, J. J. (2018). Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nature Reviews. Nephrology, 14(11), 659-660. https://doi.org/10.1038/s41581-018-0055-x

Vancouver

Sorensen CM, Holst JJ. Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nature Reviews. Nephrology. 2018;14(11):659-660. https://doi.org/10.1038/s41581-018-0055-x

Author

Sorensen, Charlotte M ; Holst, Jens J. / Renoprotective effects of dulaglutide in patients with T2DM and CKD. I: Nature Reviews. Nephrology. 2018 ; Bind 14, Nr. 11. s. 659-660.

Bibtex

@article{95994869644143baa2ad734ccb5195dc,
title = "Renoprotective effects of dulaglutide in patients with T2DM and CKD",
abstract = "The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.",
author = "Sorensen, {Charlotte M} and Holst, {Jens J}",
year = "2018",
doi = "10.1038/s41581-018-0055-x",
language = "English",
volume = "14",
pages = "659--660",
journal = "Nature Reviews Nephrology",
issn = "1759-5061",
publisher = "nature publishing group",
number = "11",

}

RIS

TY - JOUR

T1 - Renoprotective effects of dulaglutide in patients with T2DM and CKD

AU - Sorensen, Charlotte M

AU - Holst, Jens J

PY - 2018

Y1 - 2018

N2 - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

AB - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

U2 - 10.1038/s41581-018-0055-x

DO - 10.1038/s41581-018-0055-x

M3 - Comment/debate

C2 - 30171207

VL - 14

SP - 659

EP - 660

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-5061

IS - 11

ER -

ID: 203862373